JP7186222B2 - 安定なカンナビノイド組成物 - Google Patents

安定なカンナビノイド組成物 Download PDF

Info

Publication number
JP7186222B2
JP7186222B2 JP2020522788A JP2020522788A JP7186222B2 JP 7186222 B2 JP7186222 B2 JP 7186222B2 JP 2020522788 A JP2020522788 A JP 2020522788A JP 2020522788 A JP2020522788 A JP 2020522788A JP 7186222 B2 JP7186222 B2 JP 7186222B2
Authority
JP
Japan
Prior art keywords
aqueous
solvent
alkoxylating
temperature
alkoxylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020522788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527170A (ja
JP2020527170A5 (enExample
Inventor
クネーラー イルゼ
ゾヴィック トーマス
Original Assignee
ソルミック バイオテク ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソルミック バイオテク ゲーエムベーハー filed Critical ソルミック バイオテク ゲーエムベーハー
Publication of JP2020527170A publication Critical patent/JP2020527170A/ja
Publication of JP2020527170A5 publication Critical patent/JP2020527170A5/ja
Application granted granted Critical
Publication of JP7186222B2 publication Critical patent/JP7186222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020522788A 2017-07-07 2018-07-06 安定なカンナビノイド組成物 Active JP7186222B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180380.2 2017-07-07
EP17180380.2A EP3424493A1 (en) 2017-07-07 2017-07-07 Stable cannabinoid compositions
PCT/EP2018/068452 WO2019008179A1 (en) 2017-07-07 2018-07-06 STABLE CANNABINOID COMPOSITIONS

Publications (3)

Publication Number Publication Date
JP2020527170A JP2020527170A (ja) 2020-09-03
JP2020527170A5 JP2020527170A5 (enExample) 2021-07-26
JP7186222B2 true JP7186222B2 (ja) 2022-12-08

Family

ID=59315425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020522788A Active JP7186222B2 (ja) 2017-07-07 2018-07-06 安定なカンナビノイド組成物

Country Status (10)

Country Link
US (1) US11752126B2 (enExample)
EP (2) EP3424493A1 (enExample)
JP (1) JP7186222B2 (enExample)
KR (1) KR102680507B1 (enExample)
CN (2) CN115120558A (enExample)
AU (1) AU2018296679B2 (enExample)
CA (1) CA3076750A1 (enExample)
EA (1) EA202090177A1 (enExample)
IL (1) IL271892B2 (enExample)
WO (1) WO2019008179A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112915121A (zh) * 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
EP4275694A1 (de) 2022-05-13 2023-11-15 Solmic Biotech GmbH Verwendung von solubilisaten in erzeugnissen zur topischen anwendung
DE202022000150U1 (de) 2022-01-20 2022-07-07 Solmic Bio Tech Gmbh Maske für medizinische oder kosmetische Zwecke mit mizellierten Extrakten
WO2023139105A1 (de) 2022-01-20 2023-07-27 Solmic Biotech GmbH Topisch anwendbare zusammensetzung enthaltend solubilisate lipophiler wirkstoffe
CN117986017B (zh) * 2023-11-27 2025-11-21 陕西师范大学 一种（Sm2-aYa）Ba4CuBiO10纳米粉体及用其改善单畴SmBCO超导块材性能的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016176A2 (en) 2005-07-28 2007-02-08 Phoenix Biotechnology Inc. Scf extract containing cardiac glycoside
JP2007508296A (ja) 2003-05-22 2007-04-05 リポシン・インコーポレーテッド 疎水性薬物投与のための医薬組成物及び剤形
JP2010506886A (ja) 2006-10-20 2010-03-04 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 化学物質のミセルのナノ粒子
WO2012050978A1 (en) 2010-09-29 2012-04-19 MyCell Holdings Limited Formulations of ubiquinol and resveratrol esters
US20160081976A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Formulations of water-soluble derivatives of vitamin e and soft gel compositions, concentrates and powders containing same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU696855B2 (en) 1994-03-18 1998-09-17 Shire Laboratories, Inc. Emulsified drug delivery systems
JP2003500368A (ja) * 1999-05-24 2003-01-07 ソーナス ファーマシューティカルス，インコーポレイテッド 溶解度が不十分な薬剤のためのエマルジョンビヒクル
IL163808A0 (en) * 2002-03-01 2005-12-18 Yissum Res Dev Co Self emulsifying drug delivery systems for poorly soluble drugs
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
WO2007016175A1 (en) 2005-07-28 2007-02-08 Guasch Michael N Fuel repellent compositions, fabrics and articles
TWI392507B (zh) * 2006-10-20 2013-04-11 Solvay Pharm Bv 包埋的膠束奈米顆粒
HUE032158T2 (en) * 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
WO2014165672A1 (en) * 2013-04-06 2014-10-09 Igdrasol, Inc. Nanoparticle therapeutic agents, their formulations, and methods of their use
US20170119660A1 (en) * 2015-10-29 2017-05-04 Solubest Ltd Pharmaceutical compositions for transmucosal delivery

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508296A (ja) 2003-05-22 2007-04-05 リポシン・インコーポレーテッド 疎水性薬物投与のための医薬組成物及び剤形
WO2007016176A2 (en) 2005-07-28 2007-02-08 Phoenix Biotechnology Inc. Scf extract containing cardiac glycoside
JP2010506886A (ja) 2006-10-20 2010-03-04 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 化学物質のミセルのナノ粒子
WO2012050978A1 (en) 2010-09-29 2012-04-19 MyCell Holdings Limited Formulations of ubiquinol and resveratrol esters
US20160081976A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Formulations of water-soluble derivatives of vitamin e and soft gel compositions, concentrates and powders containing same

Also Published As

Publication number Publication date
IL271892A (en) 2020-02-27
JP2020527170A (ja) 2020-09-03
EP3424493A1 (en) 2019-01-09
AU2018296679A1 (en) 2020-02-20
US11752126B2 (en) 2023-09-12
KR102680507B1 (ko) 2024-07-01
KR20200037247A (ko) 2020-04-08
WO2019008179A1 (en) 2019-01-10
CA3076750A1 (en) 2019-01-10
CN115120558A (zh) 2022-09-30
IL271892B1 (en) 2023-04-01
EP3675825A1 (en) 2020-07-08
EA202090177A1 (ru) 2020-06-05
IL271892B2 (en) 2023-08-01
AU2018296679B2 (en) 2024-07-25
CN111246844A (zh) 2020-06-05
US20200237713A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
JP7336438B2 (ja) 安定なカンナビノイド組成物
JP7186222B2 (ja) 安定なカンナビノイド組成物
EP0514665B1 (fr) Mélange antioxydant liposoluble
JP4463551B2 (ja) 改良された生物学的利用能を有する製剤における高分子量で親油性で経口摂取可能な生物活性物質
ES2219800T3 (es) Microemulsion.
TWI673068B (zh) 乳液調配物
JP4117184B2 (ja) アスコルビン酸水溶液
WO2005105040A2 (en) Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
KR20140071913A (ko) 식품 조성물 및 이를 포함하는 연질 캡슐
CA2880945C (en) 2,2',6,6'-tetraisopropyl-4,4'-biphenol soft capsule and method for preparing the same
WO2018133833A1 (zh) 稳定的脂溶性活性成分组合物、微囊及其制备方法和应用
KR102438639B1 (ko) 안정성이 향상된 아스코빌테트라이소팔미테이트 수용화 페로센 나노캡슐, 그의 제조방법 및 그를 함유한 화장료 조성물
RU2303036C2 (ru) Солюбилизат из аскорбиновой кислоты и эмульгатора, смесь солюбилизатов, способ изготовления солюбилизата и его применение (варианты)
US20220287929A1 (en) Skin care product and method for its production
EA044031B1 (ru) Стабильная композиция каннабиноида
US20100196456A1 (en) Emulsion preconcentrates and micellar formulations containing wood resins
KR20160100194A (ko) 카테킨을 이용한 안정화된 레티놀 에멀젼 조성물
JPS6270317A (ja) 活性型ビタミンｄ↓３類含有製剤
ES2659282T3 (es) Preparación de beta-caroteno

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210609

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221128

R150 Certificate of patent or registration of utility model

Ref document number: 7186222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250